SCI reúne recursos sobre inmunidad y SARS-CoV-2

14. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11:1620.
13. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 2020;5:33.
12. Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence. Ecancermedicalscience. 2020;14:1022.
11. Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection. Virol Sin. 2020 Mar 31;1–4.
10. COVID-19, rheumatic diseases and immunosuppressive drugs: an appeal for medication adherence. Rheumatol Int. 2020 Mar 30;1–2.
9. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020 Mar 29;105954.
8. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Cent Sci. 2020 Mar 25;6(3):315–331.
7. Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020. Euro Surveill. 2020 Mar 19;25(11):2000266.
6. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020; doi: 10.1016/j.jpha.2020.03.001.
5. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA, 2020; doi:10.1001/jama.2020.4783.
4. Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med 2020; DOI: 10.1056/NEJMp2005630.
3. Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV). Virus Disease 2020;31:13–21.
2. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nature Communications 2020;11:1620.
1. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduction and Targeted Therapy 2020;5:33.